Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bisegliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.51 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisegliptin SCHEMBL164320 | 0.96 | DPP4 (0.64) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL196882 | 0.96 | DPP4 (0.64) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2046787 | 0.95 | DPP4 (0.62) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2047576 | 0.95 | DPP4 (0.62) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2044893 | 0.93 | DPP4 (0.60) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2046833 | 0.93 | DPP4 (0.60) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2049664 | 0.93 | DPP4 (0.60) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2048333 | 0.92 | DPP4 (0.59) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2043885 | 0.92 | DPP4 (0.59) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2049663 | 0.91 | DPP4 (0.58) | DPP4DPP8DPP9PREPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172444-A1 | METHOD FOR PURIFYING AMINOACETYLPYRROLIDINECARBONITRILE DERIVATIVE AND SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2332908-A1 | METHOD FOR PURIFYING AMINOACETYLPYRROLIDINECARBONITRILE DERIVATIVE AND SALT THEREOF | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172444-A1 | METHOD FOR PURIFYING AMINOACETYLPYRROLIDINECARBONITRILE DERIVATIVE AND SALT THEREOF | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 6/4885DPP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.